title: [The patient with uncontrolled chronic hepatitis B].
abstract: The treatment of chronic hepatitis B is now based on the using of pegylated interferon or nucleoside or nucleotide analogs. In the majority of cases, these drugs can control viral replication with an hepatitis B virus (HBV) DNA negativation after approximately 6 months of therapy. In case of primary non response, it is necessary to modify antiviral therapy and if resistance appears to combine a nucleoside and a nucleotide analog. In patients treated by nucleoside analog, if HBV DNA is not negative or do not dramatically decreases at the week 24, it is also necessary to add a nucleotide analog. However, for adefovir therapy, it is usually preferable to wait at week 48. In summary, a regular following every 3 months of HBV DNA detection by a sensitive method (Real Time PCR) allows to evaluate the therapeutic efficacy and to prevent the risk of biochemical and clinical rebound due to appearance of resistance mutations.
authors.affiliation: Clinique Universitaire d'Hépato-Gastroentérologie, Pôle DIGI-DUNE, Centre de recherche INSERM-UJF U823 IAPC, CHU de Grenoble, BP 217, 38043 Grenoble cedex, France. JPZarski@chu-grenoble.fr
authors.forename: J-P
authors.initials: JP
authors.lastname: Zarski
authors.forename: V
authors.initials: V
authors.lastname: Leroy
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D024882:Drug Resistance, Viral; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral